Ignacio
Matos García
Consultor Médico
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (30)
2023
-
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265
2022
-
Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))
ESMO Open
-
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
ESMO Open, Vol. 7, Núm. 2
2021
-
A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors
Radiology, Vol. 299, Núm. 1, pp. 109-119
-
Clarification of Definitions of Hyperprogressive Disease during Immunotherapy
JAMA Oncology
-
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
-
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
European Journal of Cancer, Vol. 155, pp. 168-178
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501
2020
-
Atypical patterns of response and progression in the era of immunotherapy combinations
Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713
-
Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria
Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855
-
Development of pharmacodynamic biomarkers for phase I trials
Phase I Oncology Drug Development (Springer International Publishing), pp. 139-158
-
Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas
Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909
-
Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial
Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317
-
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 618-627
-
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Annals of Oncology, Vol. 31, Núm. 10, pp. 1405-1412
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2019
-
Agnostic-histology approval of new drugs in oncology: Are we already there?
Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3210-3219
-
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection
Annals of Oncology
-
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study
Oncologist, Vol. 24, Núm. 1, pp. 38-46